Who:Ipsen SA and China's Foreseen Biotechnology.
What: A global licensing agreement which will see the French firm develop and commercialize FS001, an antibody-drug conjugate (ADC) with...
Ipsen Doubles Up In ADC Arena With Foreseen Alliance
Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03bn, its second antibody-drug conjugate tie-up this year, a few months after unveiling a partnership with Sutro.
More from Deals
• By
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
• By
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
• By
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
• By
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.
More from Business
• By
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
• By
A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.
• By
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.